Liver siRNA is under clinical development by Nitto BioPharma and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Liver siRNA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Liver siRNA overview
The therapeutic candidate is under development for the treatment of liver fibrosis and KRAS-driven liver cancer. It is an antisense RNAi oligonucleotide delivered through lipid-nanoparticles and is administered intravenously.
Nitto BioPharma overview
Nitto BioPharma, a subsidiary of Nitto Denko Corp, is a biopharmaceutical company that develops drug and siRNA delivery solutions. The company designs novel biodegradable delivery vehicles with the ability to target specific cells and efficiently deliver therapeutic moieties to these cells. NBPI’s major products include lipid- and polymer-based drug delivery platforms, and a siRNA lipid nanoparticle therapeutic known as ND-L02-s0201 Injection. Its drug delivery systems are designed to target specific cells, such as hepatic stellate cells, for the treatment of diseases like liver fibrosis and cirrhosis. The company’s products are used in various applications such as plasmid-based gene therapy, oligonucleotide therapy and cancer chemotherapy. Nitto BioPharma is headquartered in San Diego, California, the US.
For a complete picture of Liver siRNA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
